Answers are grounded in this paper and cite their sources.
Clinical Practice Points •Tarlatamab's onset of tumor regression can be as short as 2 weeks. •Rechallenging tarlatamab after grade 3 CRS with standard premedication is safe. •Tarlatamab combined with IMRT offers safe and highly effective CNS control. •A collapsed lung from tumor burden may re-expand with tarlatamab monotherapy.
No takes yet. Share an insight, caveat, or question.
Schieber et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: